Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$2.93 USD
-0.05 (-1.68%)
Updated May 15, 2024 04:00 PM ET
After-Market: $2.90 -0.03 (-1.02%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ANIX 2.93 -0.05(-1.68%)
Will ANIX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ANIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIX
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
ANIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
Other News for ANIX
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Anixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccines
Anixa Biosciences Forms Cancer Vaccine Partnership with Cleveland Clinic
Anixa Biosciences enters partnership to develop additional cancer vaccines
Sidoti Events, LLC's Virtual May Micro-Cap Conference